61553-71-7

Basic information

• Product Name: 4H-Pyrimido[5,4-b]indol-4-one, 3,5-dihydro-
• Synonyms: 4H-Pyrimido[5,4-b]indol-4-one, 3,5-dihydro-;1,5-dihydropyrimido[5,6-b]indol-4-one;A2095/0088059;BAS 00411376;EU-0018761;Oprea1_578262;Oprea1_704321;Oprea1_708733
• CAS NO: 61553-71-7
• Molecular Formula: C₁₀H₇N₃O
• Molecular Weight: 185.19
• Mol File: 61553-71-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4H-Pyrimido[5,4-b]indol-4-one, 3,5-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-Pyrimido[5,4-b]indol-4-one, 3,5-dihydro-(61553-71-7)
• EPA Substance Registry System: 4H-Pyrimido[5,4-b]indol-4-one, 3,5-dihydro-(61553-71-7)

Safety Data

• Hazardous Substances Data: 61553-71-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4H-Pyrimido[5,4-b]indol-4-one, 3,5-dihydrois used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique chemical structure allows for the development of new drugs with potential therapeutic benefits.
Used in Drug Discovery:
4H-Pyrimido[5,4-b]indol-4-one, 3,5-dihydrois used as a target for drug discovery due to its potential biological and pharmacological activities. Its antitumor and anti-inflammatory properties make it a promising candidate for the development of new therapeutic agents.
Used in Medicinal Chemistry Research:
4H-Pyrimido[5,4-b]indol-4-one, 3,5-dihydrois used as a subject of study in medicinal chemistry research to explore its potential applications in the treatment of various diseases and conditions. Its unique chemical structure and properties provide a foundation for the design and synthesis of novel compounds with improved therapeutic effects.
Used in Organic Chemistry:
4H-Pyrimido[5,4-b]indol-4-one, 3,5-dihydrois used in organic chemistry as a building block for the synthesis of complex organic compounds. Its heterocyclic nature and the presence of a pyrimidine and an indole ring make it a versatile component in the construction of diverse molecular architectures.

Upstream product

• 87223-77-6 ethyl 3-amino-1H-indole-2-carboxylate 
• 97311-03-0 3-(dimethylamino-methyleneamino)-1H-indole-2-carboxylic acid ethyl ester 
• 1885-29-6 anthranilic acid nitrile 
• 25116-00-1 2-acetamidobenzonitrile 

Downstream Products

• 98792-02-0 4-chloro-5H-pyrimido<5,4-b>indole 
• 107401-06-9 3-methyl-1,2,4-triazolo<4,3-c>pyrimido<5,4-b>indole 
• 107401-00-3 4-(1-piperidinyl)-5H-pyrimido<5,4-b>indole 
• 107401-01-4 4-hydrazino-5H-pyrimido<5,4-b>indole 
• 107401-03-6 N-[1-Phenyl-meth-(E)-ylidene]-N'-(5H-pyrimido[5,4-b]indol-4-yl)-hydrazine 
• 320420-18-6 (4-phenylpiperazin-1-yl)-5H-pyrimido[5,4-b]indole 
• 676601-64-2 1-{4-[2-(3,4-difluorophenyl)ethyl]piperazin-1-yl}-9H-2,4,9-triazafluoren-6-ylamine 
• 676601-59-5 1-{4-[2-(3,4-difluoro-phenyl)ethyl]-piperazin-1-yl}-6-nitro-9H-2,4,9-triaza-fluorene 

Relevant articles and documents

9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein

P-Glycoprotein (P-gp, ABCB1), multidrug resistance-associated protein 1 (MRP1, ABCC1), and breast cancer resistance protein (BCRP, ABCG2) are the three major ABC transport proteins conferring resistance to many structurally diverse anticancer agents, lead

PYRROLOPYRIMIDINE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE (MDR)

A compound which is a pyrrolopyrimidine of formula (I) wherein R1 is selected from H, Cl-C6 alkyl which is unsubstituted or substituted, (CH2)nAr1, (CH2)pNR4R5, halogen and (CH2)pX; R2 is CH2)pArl; R3 is selected from H, Cl -C6 alkyl which is unsubstituted or substituted, (CH2)pZ and (CH2)pArl; P is an unsaturated 5, 6, or 7 membered carbocyclic or heterocyclic ring which is unsubstituted or substituted; R4 and R5 which are the same or different are selected from H, Cl -C6 alkyl which is unsubstituted or substituted, (CH2)nC3-C10 cycloalkyl, (CH2)nAr1 , and (CH2)nOR6, or R4 and R5 together with the nitrogen atom to which they are attached, form a saturated five or six membered nitrogen containing heterocyclic ring which may contain one extra heteroatom selected from 0, N and S and which is unsubstituted or substituted; R6 is selected from H, Cl -C6 alkyl which is unsubstituted or substituted, C3-C10 cycloalkyl, (CH2)nOC1-C6alkyl which is unsubstituted or substituted, (CH2)nO(CH2)nAr1 , (CH2)nCO2C1-C6,alkyl which is unsubstituted or substituted and (CH2)nAr1; X is selected from CN, azide, (CH2)nNHSO2R6 and (CH2)nNHCOR6; Z is selected from CN, CO2R6 and CONR4R5; Ar1 is the same or different when more than one is present within a given substituent group and is an unsaturated C6-C10 membered carbocylic group or an unsaturated 5-11 membered heterocycle, either of which is unsubstituted or substituted; p is an integer of 1 to 6; n is the same or different when more than one is present within a given substituent group and is 0 or an integer of 1 to 6; with the proviso that the pyrrolepyrimidine compound of formula (I) is other than 1-(4-benzyl-piperazin-1-yl)-9H-2,4,9-triaza-fluorene; and the pharmaceutically acceptable salts thereof, have activity as inhibitors of MRP (multidrug resistant protein) and may thus be used to modulate multidrug resistance, for instance in potentiating the cytotoxicity of a chemotherapeutic agent.

SYNTHESIS AND SOME PROPERTIES OF 4-OXO-3,4-DIHYDRO- AND 2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDOINDOLES

The condensation of N-(2-ethoxycarbonylindol-3-yl)-N',N'-dialkylamidines with ammonia, primary amines, and hydrazines has given a series of 4-oxopyrimidoindoles which have been converted into the 4-chloro and then into the 4-methoxy, 4-dialkylamino